Answers are grounded in this paper and cite their sources.
Introduction: As a common type of clinical dementia, the prevalence rate of vascular dementia (VaD) increased rapidly in recent years, damaging both patients’ health and social-economic prospect. There is currently no effective treatment for VaD, though western medicines can slightly improve patients’ cognitive function, but not brought a significant improvement in daily life ability. Chinese herbal medicine (CHM) has been widely employed to treat dementia for more than 2000years in China. Despite the proliferation of relevant literature, there is still a lack of evidence to prove the effectiveness and safety of such therapy. Therefore, this systematic review and meta-analysis protocol is aimed to assess the efficacy and safety of CHM for VaD. Methods and analysis: Six English databases (PubMed, Web of Science, Embase, Springer, CENTRAL and WHO International Clinical Trials Registry Platform) and 4 Chinese databases (Wan fang Database, Chinese Scientific Journals Database , China National Knowledge Infrastructure Database and Chinese Biomedical Literature Database ) will be searched from the inception to July 1st, 2020. Randomized controlled trials, which participants with VaD receiving various CHM therapy versus control group, will be included in this study. Two researchers will independently obtain data, screen eligible trials, and evaluate the quality of literature. Any disagreement will be settled by a discussion with the third investigator. A comprehensive meta-analysis will be conducted using the Cochrane collaboration software (Review Manager 5.3). Ethics and dissemination: Since this article is a protocol that does not involve patients and personal information collection, ethical approval is therefore not required. This systematic review will be published in a peer-reviewed journal, presented at conferences, and will be shared on social media platforms. The review will be disseminated in a peer-reviewed journal or conference presentation. INPLASY registration number: INPLASY 202210098.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: